Home Featured Page 88

Featured

Latest

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy

Why Ketamine Is Changing Psychiatry

Trump’s Psychedelics Executive Order: Reactions From Across the Field and Beyond

Pinco Güncel Giriş Şifrənizi Yeniləmənin Əhəmiyyəti

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt...

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

PT437 – Exploring Psychedelic Therapies: Iboga, CBD, and Cannabis Paired With...

Natural Medicine Advisory Bulletin #3: August 2023

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft...

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

BREAKING: Big Pharma Company Otsuka to Acquire Mindset Pharma for CAD...

COMPASS Pathways to participate in upcoming September investor conferences

PT436 – The Power of Sound: The Magic in Live Performances,...

Cybin Set to Acquire British DMT Drug Developer Small Pharma

EDITOR PICKS

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits...

Why Ketamine Is Changing Psychiatry

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy

Why Ketamine Is Changing Psychiatry

Trump’s Psychedelics Executive Order: Reactions From Across the Field and Beyond

Pinco Güncel Giriş Şifrənizi Yeniləmənin Əhəmiyyəti

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt...

California Psychedelic Decriminalisation Bill Clears Appropriations Committee with Amendments

PT437 – Exploring Psychedelic Therapies: Iboga, CBD, and Cannabis Paired With...

Natural Medicine Advisory Bulletin #3: August 2023

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft...

FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA

BREAKING: Big Pharma Company Otsuka to Acquire Mindset Pharma for CAD...

COMPASS Pathways to participate in upcoming September investor conferences

PT436 – The Power of Sound: The Magic in Live Performances,...

Cybin Set to Acquire British DMT Drug Developer Small Pharma

EDITOR PICKS

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits...

Why Ketamine Is Changing Psychiatry

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY